title: An essential dose of cisplatin for super-selective intra-arterial infusion concomitant with radiotherapy in patient with maxillary squamous cell carcinoma.
abstract: The present study investigated the efficacy and safety of using a lower dose of cisplatin (CDDP) in super-selective intra-arterial concurrent chemoradiotherapy (SSIACRT) to treat maxillary squamous cell carcinoma. 10 patients with maxillary squamous cell carcinoma (T3 n = 6, T4a n = 4) without regional or distant metastasis were treated by SSIACRT. The CDDP dose per course was 100 mg/body, i.e. 50-80 mg/m(2). 6-9 weeks after SSIACRT, partial maxillectomy was performed on all patients. Clinical and histological responses, survival rates, and adverse events were investigated. 10 (100%) of 10 patients achieved both clinical and pathological complete or partial remission. The 3-year overall and disease-free survival rates were 100 and 90%, respectively. Grade 3 toxicity was experienced by two patients. In conclusion, the SSIACRT regimen with a lower dose of CDDP (100 mg/body) had an equivalent therapeutic outcome and lower toxic outcome compared to a higher dose of CDDP. This regimen could be an effective and safe therapeutic modality for maxillary squamous cell carcinoma except T4b and N1/2 disease.
authors.affiliation: Department of Otolaryngology, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Kanazawa
authors.forename: Hideo
authors.initials: H
authors.lastname: Shojaku
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Takakura
authors.forename: Michiro
authors.initials: M
authors.lastname: Fujisaka
authors.forename: Hirohiko
authors.initials: H
authors.lastname: Tachino
authors.forename: Yukio
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Gakuto
authors.initials: G
authors.lastname: Tomizawa
authors.forename: Hideto
authors.initials: H
authors.lastname: Kawabe
authors.forename: Hiroko
authors.initials: H
authors.lastname: Shojaku
authors.forename: Hikaru
authors.initials: H
authors.lastname: Seto
authors.forename: Kyoko
authors.initials: K
authors.lastname: Otani
authors.forename: Jyunya
authors.initials: J
authors.lastname: Fukuoka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods; D008297:Male; D008441:Maxillary Neoplasms / Q000628:therapy*; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin